Innovation Crossroads: Tech, Business, and Global Impact

A new poll shows two-thirds of workers are more likely to use GLP-1s with employer coverage, highlighting the role of cost, support, and stigma.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

Private equity giants Kelso & ARA back Beacon Communications, signaling a major expansion for the vital security and communication technology provider.

A new partnership aims to fix Southwestern Ontario's strained healthcare supply lines, promising greater reliability and cost savings for major hospitals.

A new AI platform from Gaudio Lab promises to revolutionize media localization by reconstructing audio from old films, slashing production times by 90%.

Delcath Systems is set to showcase its innovative HEPZATO KIT at SIR 2026, signaling growing adoption and a pivotal moment for its targeted cancer therapy.

Onfolio Holdings reports 36% revenue growth and positive EBITDA, but a wider net loss and auditor warnings reveal a high-stakes strategy for 2026.

OBIO awards $100K to a cancer therapy startup and launches a new training program, directly addressing the systemic funding barriers for women in life sciences.

Celebrating three decades, the Hong Kong media giant unveils a future powered by AI, deeper economic integration, and a mission to shape China's global narrative.

The diagnostics firm posts strong thyroid growth after a strategic shift, but a one-time tax adjustment inflates its impressive 2025 bottom line.

The visual app giant's pivot to AI agents drove a 65% profit surge and captured high-value global markets, redefining its future and business model.

A new partnership between Takara Bio and Hamilton promises to revolutionize RNA-seq, making high-throughput genomic analysis faster and more reliable.

Now the deadliest cancer for Americans under 50, advocates descend on Washington to demand urgent research funding for a growing national health crisis.

A French biopharma's leap in synthetic lipid production de-risks its lead drug, eyes a vast sepsis market, and creates new commercial avenues.

A new report slams the FDA for blocking vital treatments with rising costs and denials, but the agency faces a complex reality of reform and internal pressure.

With 29.7% efficient perovskite panels, Tandem PV's consistent TIME recognition highlights a major leap in solar power and a push for US manufacturing.

With a new President from the beauty world, mission-driven HealthyBaby is poised to expand its non-toxic empire beyond diapers into total early-life wellness.

With a new CFO experienced in major deals and a recent private equity infusion, MedSpeed is poised for aggressive expansion in healthcare logistics.

The Alliance for OpenUSD adds key members and a new group for characters and motion, solidifying its role in building the industrial metaverse.

In a strategic play, VIVUS is slashing the price of its oral obesity drug QSIVA, challenging the dominance of costly new injectables like Wegovy.